FOSINOPRIL SODIUM

Post-LOE

fosinopril sodium

Teva

ANDAORALTABLET

Approved

Aug 2006

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

4/8 — Partial

FOSINOPRIL SODIUM (fosinopril sodium) by Teva is clinical pharmacology mechanism of action in animals and humans, fosinopril sodium is hydrolyzed by esterases to the pharmacologically active form, fosinoprilat, a specific competitive inhibitor of angiotensin-converting enzyme (ace). Approved for hypertension, the management of heart failure, without digitalis (see ). First approved in 2006.

Drug data last refreshed Yesterday

$0.0BPart D

Mechanism of Action

CLINICAL PHARMACOLOGY Mechanism of Action In animals and humans, fosinopril sodium is hydrolyzed by esterases to the pharmacologically active form, fosinoprilat, a specific competitive inhibitor of angiotensin-converting enzyme (ACE). ACE is a peptidyl dipeptidase that catalyzes the conversion of…

Worked on FOSINOPRIL SODIUM at Teva? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

FOSINOPRIL SODIUM

Mechanism of Action

Indications (3)